The Novo Nordisk
Diabetes and Obesity Biologics Science Forum

Joseph B Martin Conference Center at Harvard Medical School,
Boston, Massachusetts
October 1-2, 2014

Novo Nordisk, a world leader in diabetes innovation, is pleased to announce a new research funding and industry partnership opportunity. Opportunities are offered under a new scheme called the Novo Nordisk Diabetes and Obesity Biologics Science Forum Program.

Novo Nordisk is inviting a limited number of leading US and Canadian academic and medical research institutions to announce this opportunity among those faculty members who could potentially have novel ideas for biologics innovation within diabetes and obesity research.

These Awards can be granted to faculty members who enter this competitive process and submit proposals for nonclinical research. Both young and established scientists at invited institutions can apply.

The areas of research in scope of the Science Forum program are:

- **Non-clinical** research related to new biologic therapeutics and targets amenable to biologics therapeutics or novel effects of known biologics in the field of Type 1 Diabetes and Type 2 Diabetes, including micro- and macrovascular complications, and obesity

The term ‘biologics’ means large peptide or protein ligands (e.g. hormones), inhibitory or modulating antibodies, immunotherapies, micro- and small interfering RNAs, and cell based concepts (e.g. stem cells). Such biologics either have to be novel or represent novel effects of a known entity.

The purpose of these Awards is to foster collaboration with Novo Nordisk R&D and facilitate translation of new ideas from early diabetes and obesity research into innovation by bringing new biologics concepts to a pre-clinical Proof of Principle milestone. Proposals will enter a two stage selection process. First, investigators need to submit a 2 page non-confidential summary to Novo Nordisk. Subsequent to this, Novo Nordisk will select proposals for full in depth presentations at a two day Science Forum where invited investigators present full details of their research proposals. Novo Nordisk will then decide on which proposals to fund following closing of the Science Forum sessions and ask for full research proposal submissions.
Types of Awards

Early Exploration

$250,000\textsuperscript{1} for a two year period

The Early Exploration Award supports nonclinical research for early-stage hypotheses that do not yet have (or only very limited) preliminary data but show considerable promise for advancing the treatment of diabetes or obesity. This includes target discovery proposals.

Proof of Principle (PoP)

$500,000\textsuperscript{1} for a two year period

The Proof of Principle (PoP) Award supports nonclinical research for the validation of early stage innovations with sufficient supporting data to conclude on nonclinical PoP studies. In general, PoP studies will require results from experiments in established animal models, in vitro human systems or reduction to practise experiments for protein technologies.

As part of the PoP Award, Applicants have the option to have additional scientific support provided by Novo Nordisk. This may include supervision and counseling by Novo Nordisk senior scientists, custom synthesis of novel biologics (e.g. peptides and proteins), and access to Novo Nordisk marketed protein therapeutics and Novo Nordisk in-house specialized lab equipment and animal models.

Proposals must be submitted no later than June 2, 2014.

Applicants must use the 2 page non-confidential summary form provided by Novo Nordisk and email it to diabetesinnovation@novonordisk.com.

For more information please contact:

Kristian Tage Hansen, PhD
Senior Director
Head of Novo Nordisk Diabetes Innovation Award Program

+45 44434838 (direct)
+45 30754838 (mobile)
diabetesinnovation@novonordisk.com

\textsuperscript{1} Direct research costs only. In addition to funding of direct expenses, the Awards will cover Institution’s standard indirect costs (Facilities and Administrative). Total funding can thus go up to double this amount dependent on the host institution F&A rate.